“I think cladribine is unique; not only in its mechanism of action, but also in the fact that it truly is an immune reconstitution therapy.”

In March 2019, cladribine joined the growing list of available therapies approved for the treatment of relapsing multiple sclerosis (RMS) and secondary progressive MS. Data collected throughout the phase 3 clinical trial program ORACLE-MS; CLARITY; CLARITY Extension) demonstrated that cladribine, the first short course, orally administered disease-modifying therapy that preferentially depletes lymphocytes, is a safe, effective, and tolerable therapy.

Led by Augusto Miravalle, MD, and his colleagues, the ongoing CLICK-MS study launched in May 2019 will examine the real-world effectiveness and safety of the drug, as well as patient reported outcomes. More specifically, it will evaluate these changes in patients with RMS who transition to cladribine after suboptimal response to injectable disease-modifying drugs.  

Miravalle, an associate professor in the department of neurology at the University of Colorado and a neurologist at Advanced Neurology of Colorado, sat down with NeurologyLive at the America’s Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum, February 27-29, 2020, to provide insight on the trial and how cladribine sets itself apart from other MS treatments. 

For more coverage of ACTRIMS 2020, click here